FDA Accepts Alvotech’s AVT16 – A New Interchangeable Biosimilar to Entyvio
Alvotech’s AVT16 biosimilar to Entyvio is under FDA review, aiming for cheaper, interchangeable treatment for gut diseases.
/ 2 items
Alvotech’s AVT16 biosimilar to Entyvio is under FDA review, aiming for cheaper, interchangeable treatment for gut diseases.
Alvotech receives FDA complete response letter for AVT05 biosimilar to Simponi, citing manufacturing facility deficiencies. Company revises 2025 revenue outlook downward.